Micafungina Sandoz

Micafungin, the active ingredient in Micafungina Sandoz, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive and esophageal candidiasis, provides prophylaxis against Candida infections in hematopoietic stem‑cell transplantation, and is used for Candida peritonitis and intra‑abdominal infections in adult and pediatric patients.

GNH USA supplies Micafungina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology clinics worldwide, with a focus on quality and regulatory compliance, and provides reliable cold‑chain logistics for temperature‑sensitive products.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis, and it is indicated for several serious Candida infections. - Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adults and children. - Esophageal candidiasis: eradication of Candida infection of the esophagus, improving swallowing function. - Prophylaxis in hematopoietic stem‑cell transplantation: prevention of invasive Candida disease during the transplant period. - Candida peritonitis and intra‑abdominal infections: therapeutic option for intra‑abdominal Candida infections following surgery or peritonitis.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Nausea: mild to moderate sensation of stomach upset. - Headache: occasional mild headache reported. - Vomiting: occasional episodes post‑infusion. - Infusion‑related reactions: flushing, chills, or hypotension. - Elevated liver enzymes: transient increase in ALT or AST levels. Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Anaphylaxis: acute hypersensitivity reaction with respiratory distress. - Stevens‑Johnson syndrome: rare severe skin reaction with mucosal involvement. - Renal impairment: acute kidney injury reported in rare cases.

Before initiating Micafungin therapy, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess and monitor in patients with renal impairment. - Hepatic function: evaluate baseline liver enzymes and monitor during treatment. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications for possible interactions. - Infusion monitoring: administer through a dedicated line and observe for reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, and interactions are classified by their clinical significance. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin plasma levels. - Co‑administration with other echinocandins: risk of additive toxicity. Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may elevate micafungin concentrations. - Immunosuppressants (e.g., tacrolimus, cyclosporine): require level monitoring. - Anticoagulants (e.g., warfarin): monitor INR for possible changes.